Suchergebnisse - "Felip, Enriqueta"

PubPharm (31)

1

The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer

enthalten in: Cancer treatment reviews | 2024

von Ciardiello, F. | Hirsch, F. | Pirker, R. | +3

2

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Tang, K. | Cho, B. | +126

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF9. - PMID 37878779

3

HERTHENA-Lung01 : a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

enthalten in: Future oncology (London, England) | 2023

von Yu, H. | Yang, J. | Hayashi, H. | +10

4

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain : a Delphi consensus panel study

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023

von Isla, D. | Felip, E. | Garrido, P. | +5

5

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

enthalten in: Expert review of anticancer therapy | 2023

von Yang, J. | Zhou, C. | Jänne, P. | +18

6

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer : Results of a phase 2, single-arm, open-label study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Tan, D. | Kim, S. | Ponce Aix, S. | +17

7

MARIPOSA : phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

enthalten in: Future oncology (London, England) | 2022

von Cho, B. | Felip, E. | Hayashi, H. | +8

8

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer : A Phase 1/2 Open-label Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Zhou, C. | Ramalingam, S. | Kim, T. | +15

ErratumIn: JAMA Oncol. 2022 Feb 24;:. - PMID 35201294

9

Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer

enthalten in: British journal of cancer | 2021

von Martinez-Marti, A. | Felip, E. | Mancuso, F. | +13

10

LungBEAM : A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

enthalten in: Cancer medicine | 2021

von Garrido, P. | Paz-Ares, L. | Majem, M. | +17